Alnylam receives EU marketing authorisation for hATTR amyloidosis therapy

Amvuttra is indicated to treat hereditary transthyretin-mediated amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy. Credit: Ed Uthman, MD/ commons.wikimedia.org.